FOLH1 and posterior cortical atrophy: Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) is a well-validated target for imaging and treatment of PCa, as it is overexpressed in most primary PCa lesions along with distant metastatic lesions and metastatic lymph nodes [8].